A Study of Nivolumab in Patients With Head and Neck Cancer.
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
BIOLOGICAL: Nivolumab
Overall Survival, 3 Years
Overall Survival within Sub groups, 3 year|Progression-free survival (PFS), 3 Years|Overall response rate (ORR), 3 years|Best overall response rate (BORR), 3 years|Time to response (TTR), 3 years|Duration of response (DOR), 3 years|Incidents of Adverse Events (AEs), 3 years|Incidents of immune-related Adverse Events, 3 years|Incident of treatment-related Adverse Events, 3 years|Number of socio-demographic characteristics in adult patients with SCCHN, 3 years|Number of clinical characteristics in adult patients with SCCHN, 3 Years|Number of treatment characteristics in adult patients with SCCHN, 3 Years|Functional Assessment of Cancer Therapy - Head & Neck (FACT-H&N) Score, 3 Years|Quality of life of caregiver (CarGoQoL ) Score, 3 Years|Supportive Care Needs Survey for Partners and Caregivers (SCNS-P&C) Assessment score, 3 Years|European Quality of Life-5 Dimensions (EQ-5D) score, 3 Years
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy